[HTML][HTML] Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following …

IA Mayer, F Zhao, CL Arteaga… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease
(RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence …

Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer

YK Chae, AA Davis, S Jain, C Santa-Maria… - Molecular cancer …, 2017 - AACR
While identifying genomic alterations in tumor tissue is the current gold-standard technique
for molecular profiling, circulating tumor DNA (ctDNA) represents a noninvasive method of …

[HTML][HTML] A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer

CA Santa-Maria, T Kato, JH Park, K Kiyotani… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors produce modest responses in metastatic breast cancer,
however, combination approaches may improve responses. A single arm pilot study was …

[HTML][HTML] Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2− negative endocrine-refractory metastatic breast …

AN Shah, L Flaum, I Helenowski… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Response rates to single agent immune checkpoint blockade in unselected
pretreated HER2− negative metastatic breast cancer (MBC) are low. However, they may be …

[HTML][HTML] Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast …

AA Davis, Q Zhang, L Gerratana, AN Shah… - Breast Cancer …, 2019 - Springer
Purpose Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor
cells (CTCs), can be used to understand disease prognosis, tumor heterogeneity, and …

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer …

L Gerratana, Q Zhang, AN Shah, AA Davis… - Critical Reviews in …, 2020 - Elsevier
Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for
advanced disease characterization because of its ability both to capture the tumor's …

[HTML][HTML] Landscape of circulating tumour DNA in metastatic breast cancer

AA Davis, S Jacob, L Gerratana, AN Shah, F Wehbe… - …, 2020 - thelancet.com
Background We describe the genomic landscape of circulating tumour DNA (ctDNA) across
pathological subtypes of metastatic breast cancer. Methods 255 clinically annotated patients …

The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer

S Jacob, AA Davis, L Gerratana, M Velimirovic… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive
longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize …

Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer

L Gerratana, AA Davis, Q Zhang, D Basile… - JCO Precision …, 2021 - ascopubs.org
PURPOSE Liquid biopsy–based biomarkers, including circulating tumor cells (CTCs) and
circulating tumor DNA (ctDNA), are increasingly important for the characterization of …

Advances in endocrine therapy for postmenopausal metastatic breast cancer

LE Flaum, WJ Gradishar - Optimizing Breast Cancer Management, 2018 - Springer
A majority of breast cancers are hormone receptor (HR) positive and are responsive to
various types of hormone manipulation. Endocrine therapy is the preferred first-line therapy …